• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19.

作者信息

Williams Bryan, Zhang Yi

机构信息

Institute of Cardiovascular Sciences, University College London, and National Institute for Health Research University College London Biomedical Research Centre, London, W1T 7DN, UK.

Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.

出版信息

Lancet. 2020 May 30;395(10238):1671-1673. doi: 10.1016/S0140-6736(20)31131-4. Epub 2020 May 14.

DOI:10.1016/S0140-6736(20)31131-4
PMID:32416786
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7255199/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6de/7255199/b1c97e46e85e/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6de/7255199/b1c97e46e85e/fx1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6de/7255199/b1c97e46e85e/fx1_lrg.jpg

相似文献

1
Hypertension, renin-angiotensin-aldosterone system inhibition, and COVID-19.高血压、肾素-血管紧张素-醛固酮系统抑制与2019冠状病毒病
Lancet. 2020 May 30;395(10238):1671-1673. doi: 10.1016/S0140-6736(20)31131-4. Epub 2020 May 14.
2
Renin-angiotensin-aldosterone system inhibitors to treat COVID-19?肾素-血管紧张素-醛固酮系统抑制剂用于治疗新型冠状病毒肺炎？
CMAJ. 2020 Jun 29;192(26):E728. doi: 10.1503/cmaj.76023.
3
Decreased Mortality of COVID-19 With Renin-Angiotensin-Aldosterone System Inhibitors Therapy in Patients With Hypertension: A Meta-Analysis.肾素-血管紧张素-醛固酮系统抑制剂治疗高血压患者可降低COVID-19死亡率：一项荟萃分析
Hypertension. 2020 Aug;76(2):e13-e14. doi: 10.1161/HYPERTENSIONAHA.120.15572. Epub 2020 May 27.
4
Could renin-angiotensin-aldosterone system inhibitors be used for hypertensive patients with coronavirus disease 2019?肾素-血管紧张素-醛固酮系统抑制剂能否用于2019冠状病毒病高血压患者？
J Hypertens. 2020 Jun;38(6):1191-1192. doi: 10.1097/HJH.0000000000002474.
5
Renin-Angiotensin-Aldosterone System Inhibitors Impact on COVID-19 Mortality: What's Next for ACE2?肾素-血管紧张素-醛固酮系统抑制剂对2019冠状病毒病死亡率的影响：血管紧张素转换酶2的下一步是什么？
Clin Infect Dis. 2020 Nov 19;71(16):2129-2131. doi: 10.1093/cid/ciaa627.
6
The Renin-Angiotensin-Aldosterone System in Coronavirus Infection-Current Considerations During the Pandemic.冠状病毒感染中的肾素-血管紧张素-醛固酮系统——大流行期间的当前思考
J Cardiothorac Vasc Anesth. 2020 Jul;34(7):1717-1719. doi: 10.1053/j.jvca.2020.04.010. Epub 2020 Apr 16.
7
Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19.新型冠状病毒肺炎中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Jun 11;382(24):e92. doi: 10.1056/NEJMc2013707. Epub 2020 May 19.
8
Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19.新型冠状病毒肺炎中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Jun 11;382(24):e92. doi: 10.1056/NEJMc2013707. Epub 2020 May 19.
9
Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19.新型冠状病毒肺炎中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Jun 11;382(24):e92. doi: 10.1056/NEJMc2013707. Epub 2020 May 19.
10
Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新型冠状病毒肺炎
N Engl J Med. 2020 Jun 18;382(25):2462-2464. doi: 10.1056/NEJMe2012924. Epub 2020 May 1.

引用本文的文献

1
Impact of Hypertension and Antihypertensive Treatment on COVID-19 Severity: A Retrospective Observational Study in Ternopil Region, Ukraine.高血压及降压治疗对新冠病毒疾病严重程度的影响：乌克兰捷尔诺波尔地区的一项回顾性观察研究
Ther Clin Risk Manag. 2025 Jun 25;21:995-1007. doi: 10.2147/TCRM.S527151. eCollection 2025.
2
Association between renin-angiotensin antagonism and COVID-19-related mortality in patients with essential hypertension: A single center, retrospective cohort study.肾素-血管紧张素拮抗与原发性高血压患者 COVID-19 相关死亡率的关系：一项单中心回顾性队列研究。
J Clin Hypertens (Greenwich). 2024 Sep;26(9):1039-1044. doi: 10.1111/jch.14869. Epub 2024 Jul 14.
3

本文引用的文献

1
Response by Zhang et al to Letter Regarding Article, "Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19".张等人对关于文章《住院使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与 COVID-19 住院高血压患者死亡率的关联》的信件的回复
Circ Res. 2020 Jun 5;126(12):e142-e143. doi: 10.1161/CIRCRESAHA.120.317242. Epub 2020 Jun 4.
2
Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust.血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂与英国多地点急性医院信托的严重 COVID-19 感染无关。
Eur J Heart Fail. 2020 Jun;22(6):967-974. doi: 10.1002/ejhf.1924. Epub 2020 Jul 7.
3
Babesia BdFE1 esterase is required for the anti-parasitic activity of the ACE inhibitor fosinopril.
疟原虫 BdFE1 酯酶对于 ACE 抑制剂福辛普利的抗寄生虫活性是必需的。
J Biol Chem. 2023 Nov;299(11):105313. doi: 10.1016/j.jbc.2023.105313. Epub 2023 Oct 4.
4
Interaction of COVID-19 With Common Cardiovascular Disorders.COVID-19 与常见心血管疾病的相互作用。
Circ Res. 2023 May 12;132(10):1259-1271. doi: 10.1161/CIRCRESAHA.122.321952. Epub 2023 May 11.
5
studies of the renin-angiotensin system in human adipose tissue/adipocytes and possible relationship to SARS-CoV-2: a scoping review.对人类脂肪组织/脂肪细胞中的肾素-血管紧张素系统的研究及其与 SARS-CoV-2 的可能关系：范围综述。
Adipocyte. 2023 Dec;12(1):2194034. doi: 10.1080/21623945.2023.2194034.
6
Immune system changes in those with hypertension when infected with SARS-CoV-2.高血压患者感染 SARS-CoV-2 时免疫系统的变化。
Cell Immunol. 2022 Aug;378:104562. doi: 10.1016/j.cellimm.2022.104562. Epub 2022 Jun 9.
7
An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19.关于新型冠状病毒肺炎潜在治疗药物候选物、疫苗的最新综述以及对已提交专利的见解。
Curr Res Pharmacol Drug Discov. 2021;2:100063. doi: 10.1016/j.crphar.2021.100063. Epub 2021 Oct 8.
8
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.ESC 指导意见：COVID-19 大流行期间心血管疾病的诊断和管理：第 2 部分——治疗途径、治疗和随访。
Cardiovasc Res. 2022 Jun 22;118(7):1618-1666. doi: 10.1093/cvr/cvab343.
9
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis.欧洲心脏病学会在 COVID-19 大流行期间心血管疾病的诊断和管理指南：第 1 部分-流行病学、病理生理学和诊断。
Cardiovasc Res. 2022 May 6;118(6):1385-1412. doi: 10.1093/cvr/cvab342.
10
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis.欧洲心脏病学会在 COVID-19 大流行期间心血管疾病的诊断和管理指南：第 1 部分-流行病学、病理生理学和诊断。
Eur Heart J. 2022 Mar 14;43(11):1033-1058. doi: 10.1093/eurheartj/ehab696.
Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂与 COVID-19 住院风险的相关性：一项基于病例的队列研究
Lancet. 2020 May 30;395(10238):1705-1714. doi: 10.1016/S0140-6736(20)31030-8. Epub 2020 May 14.
4
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.肾素-血管紧张素-醛固酮系统抑制剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2441-2448. doi: 10.1056/NEJMoa2008975. Epub 2020 May 1.
5
Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.肾素-血管紧张素-醛固酮系统阻滞剂与新冠病毒风险。
N Engl J Med. 2020 Jun 18;382(25):2431-2440. doi: 10.1056/NEJMoa2006923. Epub 2020 May 1.
6
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.心血管疾病、药物治疗与新冠病毒感染相关死亡率
N Engl J Med. 2020 Jun 18;382(25):e102. doi: 10.1056/NEJMoa2007621. Epub 2020 May 1.
7
Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China.中国武汉因 2019 年冠状病毒病（COVID-19）感染而住院的高血压患者中，肾素-血管紧张素系统抑制剂与严重程度或死亡风险的关系。
JAMA Cardiol. 2020 Jul 1;5(7):825-830. doi: 10.1001/jamacardio.2020.1624.
8
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?高血压和糖尿病患者感染新型冠状病毒肺炎（COVID-19）的风险会增加吗？
Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11.
9
Structure analysis of the receptor binding of 2019-nCoV.2019新型冠状病毒受体结合的结构分析
Biochem Biophys Res Commun. 2020 Feb 17;525(1):135-40. doi: 10.1016/j.bbrc.2020.02.071.
10
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.